Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Bivalent rLP2086 (Trumenba®): Development of a well-characterized vaccine through commercialization.

Sunasara K, Cundy J, Srinivasan S, Evans B, Sun W, Cook S, Bortell E, Farley J, Griffin D, Bailey Piatchek M, Arch-Douglas K.

Vaccine. 2018 May 24;36(22):3180-3189. doi: 10.1016/j.vaccine.2017.03.100. Epub 2017 Apr 19.

PMID:
28433330
2.

Evaluation of a 74-kDa transferrin-binding protein from Moraxella (Branhamella) catarrhalis as a vaccine candidate.

Chen D, McMichael JC, VanDerMeid KR, Masi AW, Bortell E, Caplan JD, Chakravarti DN, Barniak VL.

Vaccine. 1999 Aug 20;18(1-2):109-18.

PMID:
10501241
3.

Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitope.

McMichael JC, Fiske MJ, Fredenburg RA, Chakravarti DN, VanDerMeid KR, Barniak V, Caplan J, Bortell E, Baker S, Arumugham R, Chen D.

Infect Immun. 1998 Sep;66(9):4374-81.

4.

Purification of an antigenic vaccine protein by selective displacement chromatography.

Shukla AA, Hopfer RL, Chakravarti DN, Bortell E, Cramer SM.

Biotechnol Prog. 1998 Jan-Feb;14(1):92-101.

PMID:
9496673

Supplemental Content

Loading ...
Support Center